ciglitazone has been researched along with Osteosarcoma in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Four osteosarcoma cell lines (143B, MNNG/HOS, MG-63, and TE-85) were treated with proliferator-activated receptor (PPAR)gamma agonists, troglitazone and ciglitazone, and a retinoid X receptor (RXR) ligand, 9-cis retinoic acid." | 3.71 | Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. ( Breyer, B; Cheng, H; Feng, T; Haydon, RC; He, TC; Ishikawa, A; Jiang, W; Montag, A; Peabody, T; Simon, MA; Zhou, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haydon, RC | 1 |
| Zhou, L | 1 |
| Feng, T | 1 |
| Breyer, B | 1 |
| Cheng, H | 1 |
| Jiang, W | 1 |
| Ishikawa, A | 1 |
| Peabody, T | 1 |
| Montag, A | 1 |
| Simon, MA | 1 |
| He, TC | 1 |
1 other study available for ciglitazone and Osteosarcoma
| Article | Year |
|---|---|
Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Division; Chromans; Dose- | 2002 |